Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia

Boehringer Ingelheim, Click Therapeutics ink $500M+ digital therapeutics development, commercialization deal (MobiHealthNews): International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. The treatment, referred to as CT-155, will be a mobile app built on Click’s proprietary tech platform, the companies said … With this big ticket deal, Boehringer Ingelheim becomes the latest major pharma company to bet big on what many in the industry still consider to be an unexplored treatment modality. Of note, the company said in the announcement that its viewing the digital therapeutic as “a meaningful new treatment category” for neuropsychiatric disorders such as schizophrenia. Either alone or with a drug, they wrote, this type of approach could potentially improve access to the kind of tailored psychosocial interventions that are recommended in treatment guidelines for schizophrenia, but infrequently delivered. The Announcement: Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia (press release): Boehringer Ingelheim and Click Therapeutics today announced they have entered into a collaboration for the development and commercialization of a prescription-based digital the...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology Boehringer Ingelheim Click Therapeutics CT-155 digital therapeutic digital treatment disorders neuropsychiatric neuropsychiatric disorders pharma prescription-based schizophreni Source Type: blogs